Bone News and Research

RSS

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.

7 Jun 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer.

7 Jun 2011

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis, Inc. today reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in a phase 2 adaptive randomized discontinuation trial (RDT).

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Women with low bone density more likely to benefit from bisphosphonate drug

Women with low bone density are seven times more likely to benefit from a bisphosphonate drug when their vitamin D blood levels are above recent recommendations from the Institute of Medicine (IOM) as adequate for bone health.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).

6 Jun 2011

FDA clears ArthroCare's Spartan 6.5 Needled Anchor

ArthroCare® Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Spartan™ 6.5 Needled Anchor (Spartan). The Spartan device is a preloaded threaded anchor indicated for use in fixation of soft tissue to bone, such as during a rotator cuff repair.

6 Jun 2011

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological.

6 Jun 2011

$Skin wrinkles may allow identification of fracture risk in early menopausal women$

Skin wrinkles may allow identification of fracture risk in early menopausal women

A news study finds that the worse a woman's skin wrinkles are during the first few years of menopause, the lower her bone density is. The results will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

$Stem cell transplant may help promote bone fracture healing$

Stem cell transplant may help promote bone fracture healing

Researchers at the University of North Carolina at Chapel Hill School of Medicine have shown in an animal study that transplantation of adult stem cells enriched with a bone-regenerating hormone can help mend bone fractures that are not healing properly.

6 Jun 2011

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. and discussed at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) by Farhad Ravandi, M.D., who presided over the ASCO discussion session, both of the University of Texas M.D. Anderson Cancer Center.

6 Jun 2011

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Older adults with subclinical hyperthyroidism may face higher risk of dying

A common hormone abnormality in older adults—a mild form of overactive thyroid called subclinical hyperthyroidism—is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Nonmenstruating female athletes have abnormal bone structure: Study

Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

$Bariatric weight-loss surgery may increase risk of fractures$

Bariatric weight-loss surgery may increase risk of fractures

People who have had gastric bypass surgery or other bariatric weight-loss surgery have an even higher increased risk of breaking bones than previously found. These study findings will be presented Tuesday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Wrinkles and bone health: Connection

According to a new study, women who have severe skin wrinkles during the first few years of menopause also appear to have lower bone mineral density.

5 Jun 2011

Bone News and Research

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Women with low bone density more likely to benefit from bisphosphonate drug

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

FDA clears ArthroCare's Spartan 6.5 Needled Anchor

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Skin wrinkles may allow identification of fracture risk in early menopausal women

Stem cell transplant may help promote bone fracture healing

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Older adults with subclinical hyperthyroidism may face higher risk of dying

Nonmenstruating female athletes have abnormal bone structure: Study

Bariatric weight-loss surgery may increase risk of fractures

Wrinkles and bone health: Connection

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News